CLEC2B

Summary

CLEC2B (C-type lectin domain family 2 member B, HGNC:2053) is a protein-coding gene on chromosome 12p13.31, encoding C-type lectin domain family 2 member B (Q92478). Membrane-bound protein expressed on myeloid cells which acts as a ligand to stimulate the activating receptor NKp80/KLRF1, expressed on the surface of natural killer (NK) cells.

This gene encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. Members of this family share a common protein fold and have diverse functions, such as cell adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune response. The encoded type 2 transmembrane protein may function as a cell activation antigen. An alternative splice variant has been described but its full-length sequence has not been determined. This gene is closely linked to other CTL/CTLD superfamily members on chromosome 12p13 in the natural killer gene complex region.

Source: NCBI Gene 9976 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 28 total
• MANE Select transcript: NM_005127

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2053
Approved symbol	CLEC2B
Name	C-type lectin domain family 2 member B
Location	12p13.31
Locus type	gene with protein product
Status	Approved
Aliases	AICL, HP10085
Ensembl gene	ENSG00000110852
Ensembl biotype	protein_coding
OMIM	603242
Entrez	9976

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 9 protein_coding, 2 retained_intron

ENST00000228438, ENST00000538152, ENST00000539028, ENST00000540743, ENST00000893503, ENST00000893504, ENST00000893505, ENST00000893506, ENST00000893507, ENST00000893508, ENST00000964946

RefSeq mRNA: 1 — MANE Select: NM_005127 NM_005127

CCDS: CCDS8605

Canonical transcript exons

ENST00000228438 — 5 exons

Exon	Start	End
ENSE00000718717	9854381	9854484
ENSE00000718723	9857474	9857637
ENSE00000821831	9852369	9853408
ENSE00002212889	9869205	9869354
ENSE00003673571	9862499	9862573

Expression profiles

Bgee: expression breadth ubiquitous, 283 present calls, max score 98.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.7580 / max 2037.3463, expressed in 1095 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
129439	31.2236	1062
129440	2.2128	722
129443	0.6224	180
129438	0.3785	191
129442	0.1751	77
129441	0.1457	74

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper leg skin	UBERON:0004262	98.85	gold quality
skin of hip	UBERON:0001554	98.60	gold quality
periodontal ligament	UBERON:0008266	97.80	gold quality
gluteal muscle	UBERON:0002000	97.62	gold quality
vena cava	UBERON:0004087	96.95	gold quality
pericardium	UBERON:0002407	96.69	gold quality
mononuclear cell	CL:0000842	96.63	gold quality
penis	UBERON:0000989	96.61	gold quality
monocyte	CL:0000576	96.58	gold quality
mammalian vulva	UBERON:0000997	96.55	gold quality
leukocyte	CL:0000738	96.53	gold quality
granulocyte	CL:0000094	96.19	gold quality
decidua	UBERON:0002450	96.13	gold quality
gingiva	UBERON:0001828	96.12	gold quality
upper arm skin	UBERON:0004263	95.90	gold quality
gingival epithelium	UBERON:0001949	95.80	gold quality
mucosa of urinary bladder	UBERON:0001259	95.44	gold quality
skin of leg	UBERON:0001511	95.43	gold quality
zone of skin	UBERON:0000014	95.30	gold quality
visceral pleura	UBERON:0002401	95.17	gold quality
skin of abdomen	UBERON:0001416	95.09	gold quality
left ovary	UBERON:0002119	95.08	gold quality
palpebral conjunctiva	UBERON:0001812	94.53	gold quality
pleura	UBERON:0000977	94.50	gold quality
spleen	UBERON:0002106	94.40	gold quality
esophagus squamous epithelium	UBERON:0006920	94.31	gold quality
calcaneal tendon	UBERON:0003701	94.10	gold quality
bone marrow	UBERON:0002371	94.07	gold quality
right ovary	UBERON:0002118	94.03	gold quality
subcutaneous adipose tissue	UBERON:0002190	93.93	gold quality

Single-cell (SCXA)

Detected in 18 experiment(s), a significant marker in 14.

Experiment	Marker?	Max mean expression
E-MTAB-8884	yes	1182.12
E-GEOD-110499	yes	282.56
E-CURD-122	yes	44.93
E-HCAD-1	yes	43.44
E-HCAD-8	yes	33.87
E-HCAD-4	yes	29.06
E-MTAB-10287	yes	28.23
E-HCAD-10	yes	28.00
E-CURD-46	yes	19.65
E-CURD-88	yes	16.05
E-MTAB-8410	yes	12.83
E-GEOD-135922	yes	11.10
E-MTAB-5061	yes	5.93
E-CURD-95	no	783.72
E-MTAB-10290	no	584.46

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI2

miRNA regulators (miRDB)

60 targeting CLEC2B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-3119	99.92	71.34	2390
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-6832-5P	99.58	64.82	1132
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-582-5P	99.47	70.79	2635
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669

Literature-anchored findings (GeneRIF, showing 9)

• NKp80 is expressed on a highly responsive subset of effector memory CD8 T cells with an inflammatory NK-like phenotype and promotes T-cell responses toward AICL-expressing cells. (PMID:18922855)
• expressed in primary liver cancers (PMID:20663776)
• our data report a previously unrecognized regulatory circuit enabling autonomous control of human NK cell responses via the NKp80-AICL axis. (PMID:23929856)
• Lipid rafts do not directly contribute to CLEC-2 receptor activation in platelets. (PMID:25462818)
• Data suggest that vascular smooth muscle cells (VSMCs) stimulate platelets through platelet receptor CLEC-2, possibly leading to thrombus formation after plaque erosion. (PMID:26418160)
• Review of C-type lectin-like receptor 2 and podoplanin interactions [review] (PMID:27960039)
• our data demonstrate that AICL expression and surfacing are tightly controlled by several independent cellular posttranslational mechanisms. (PMID:29980609)
• Plasma soluble C-type lectin-like receptor-2 is associated with the risk of coronary artery disease. (PMID:31280468)
• Association between c-type lectin-like receptor 2 and microsatellite instability in colorectal cancer: a cross-sectional study. (PMID:35902826)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-193e13.5	ENSDARG00000052656
danio_rerio		ENSDARG00000074732
danio_rerio	si:dkey-26c10.5	ENSDARG00000088023
danio_rerio	si:ch211-170d8.8	ENSDARG00000090945
drosophila_melanogaster	rgn	FBGN0261258
caenorhabditis_elegans		WBGENE00009156
caenorhabditis_elegans		WBGENE00013008

Paralogs (23): CLEC2D (ENSG00000069493), CD69 (ENSG00000110848), KLRB1 (ENSG00000111796), KLRD1 (ENSG00000134539), KLRC1 (ENSG00000134545), KLRG1 (ENSG00000139187), KLRF1 (ENSG00000150045), CLEC1A (ENSG00000150048), CLEC1B (ENSG00000165682), CLEC7A (ENSG00000172243), CLEC12A (ENSG00000172322), OLR1 (ENSG00000173391), KLRC4 (ENSG00000183542), CLEC2A (ENSG00000188393), KLRG2 (ENSG00000188883), CLEC9A (ENSG00000197992), KLRC2 (ENSG00000205809), KLRC3 (ENSG00000205810), KLRK1 (ENSG00000213809), CLEC2L (ENSG00000236279), CLEC12B (ENSG00000256660), KLRF2 (ENSG00000256797), CLEC5A (ENSG00000258227)

Protein

Protein identifiers

C-type lectin domain family 2 member B — Q92478 (reviewed: Q92478)

Alternative names: Activation-induced C-type lectin, C-type lectin superfamily member 2, IFN-alpha-2b-inducing-related protein 1

All UniProt accessions (2): Q92478, F5H631

UniProt curated annotations — full annotation on UniProt →

Function. Membrane-bound protein expressed on myeloid cells which acts as a ligand to stimulate the activating receptor NKp80/KLRF1, expressed on the surface of natural killer (NK) cells. In turn, stimulates NK-cell cytotoxicity and cytokine production leading to the cytolysis of malignant CLEC2B-expressing myeloid cells.

Subunit / interactions. Homodimer. Interacts with NKp80/KLRF1.

Subcellular location. Cell membrane. Golgi apparatus membrane.

Tissue specificity. Expressed preferentially in lymphoid tissues, and in most hematopoietic cell types.

Post-translational modifications. (Microbial infection) Ubiquitinated by human herpesvirus 8 protein K5, leading to endolysosomal degradation. N-linked glycosylated; required to enable surface expression and the extent of surface expression correlates with the number of functional conventional N-glycosylation sites.

Induction. By TLR activation. By IL12 and IL18.

RefSeq proteins (1): NP_005118* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001304	C-type_lectin-like	Domain
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR033992	NKR-like_CTLD	Domain
IPR050828	C-type_lectin/matrix_domain	Family

Pfam: PF00059

UniProt features (15 total): disulfide bond 3, sequence conflict 3, glycosylation site 3, topological domain 2, chain 1, mutagenesis site 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92478-F1	92.25	0.79

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 123–136, 35–46, 63–144

Glycosylation sites (3): 57, 62, 100

Mutagenesis-validated functional residues (1):

Position	Phenotype
87	complete loss of dimerization.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell

MSigDB gene sets: 235 (showing top): MCLACHLAN_DENTAL_CARIES_UP, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, MODULE_151, MODULE_45, MODULE_64, GOBP_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN, MODULE_118, GOBP_REGULATION_OF_IMMUNE_RESPONSE, MODULE_75, ONKEN_UVEAL_MELANOMA_UP, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, BLALOCK_ALZHEIMERS_DISEASE_UP, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, MODULE_410

GO Biological Process (2): NK T cell activation (GO:0051132), signal transduction (GO:0007165)

GO Molecular Function (4): carbohydrate binding (GO:0030246), identical protein binding (GO:0042802), receptor ligand activity (GO:0048018), protein binding (GO:0005515)

GO Cellular Component (4): Golgi membrane (GO:0000139), plasma membrane (GO:0005886), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
alpha-beta T cell activation	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
protein binding	1
signaling receptor binding	1
signal transduction	1
signaling receptor activator activity	1
Golgi apparatus	1
bounding membrane of organelle	1
membrane	1
cell periphery	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

718 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CLEC2B	KLRF1	Q9NZS2	987
CLEC2B	SLAMF6	Q96DU3	783
CLEC2B	KLRC4	O43908	780
CLEC2B	KLRF2	D3W0D1	726
CLEC2B	NCR1	O76036	693
CLEC2B	HLA-E	P13747	669
CLEC2B	NCR2	O95944	641
CLEC2B	NCR3	O14931	625
CLEC2B	MICB	P79525	611
CLEC2B	KLRK1	P26718	516
CLEC2B	CLEC3A	O75596	513
CLEC2B	ICAM1	P05362	499
CLEC2B	OLR1	P78380	488
CLEC2B	CD27	P26842	482
CLEC2B	TLR9	Q9NR96	474

IntAct

27 interactions, top by confidence:

A	B	Type	Score
CLEC2B	CLEC2B	psi-mi:“MI:0407”(direct interaction)	0.560
CLEC2B	CLEC2B	psi-mi:“MI:0195”(covalent binding)	0.560
CLEC2B	A2M	psi-mi:“MI:0915”(physical association)	0.560
CLEC2B	DNM2	psi-mi:“MI:0915”(physical association)	0.560
CLEC2B	TOR1A	psi-mi:“MI:0915”(physical association)	0.560
HTT	CLEC2B	psi-mi:“MI:0915”(physical association)	0.560
CLEC2B	ASPHD2	psi-mi:“MI:0914”(association)	0.530
CLEC2B	KLRF1	psi-mi:“MI:0407”(direct interaction)	0.440
	ENO1	psi-mi:“MI:0914”(association)	0.350
CLEC2B	DEGS1	psi-mi:“MI:0914”(association)	0.350
CLEC2B	ADAM10	psi-mi:“MI:0914”(association)	0.350
AFG2A	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (147): CLEC2B (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), DGAT1 (Affinity Capture-MS), ADAMTS2 (Affinity Capture-MS), FAR2 (Affinity Capture-MS), EIF2B1 (Affinity Capture-MS), FAM69A (Affinity Capture-MS), FAM114A2 (Affinity Capture-MS), SUN1 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), TMEM199 (Affinity Capture-MS), PON2 (Affinity Capture-MS), USP22 (Affinity Capture-MS), KIAA2013 (Affinity Capture-MS), SLC4A7 (Affinity Capture-MS)

ESM2 similar proteins: A0A0E4BZH1, A4KWA1, D3W0D1, O35778, O54707, P27471, P27812, P27814, P78380, P79391, Q0VCS6, Q0ZUP0, Q0ZUP1, Q12918, Q13241, Q2HXU8, Q38HS3, Q49BZ4, Q58DF9, Q5NKN2, Q5NKN4, Q5QGZ9, Q60651, Q60652, Q60653, Q60660, Q60682, Q63378, Q64329, Q6QLQ4, Q6UVW9, Q80ZC8, Q863H3, Q8BWY2, Q8C567, Q8CJC7, Q8HZR8, Q8MHY9, Q8NC01, Q8VD98

Diamond homologs: A4D1S0, O88713, P0C7M8, P0C7M9, Q0ZCA7, Q3UM83, Q92478, Q96E93, A4KWA5, A4KWA6, A4KWA8, O70156, O89335, P06734, P08290, P14370, P37217, P49259, P79391, Q07108, Q0H8B9, Q5M9I1, Q5QGZ9, Q60660, Q6QLQ4, Q6UVW9, Q6UXN8, Q80XD9, Q8BWY2, Q8C1T8, Q8N1N0, Q8VI21, Q91V08, Q925N7, Q9D676, Q9UBG0, Q9UHP7, Q9WVF9, Q9XTA8, A4KWA1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

28 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	19
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

682 predictions. Top by Δscore:

Variant	Effect	Δscore
12:9857638:C:CC	acceptor_gain	1.0000
12:9857633:TTTAA:T	acceptor_gain	0.9900
12:9857634:TTAA:T	acceptor_gain	0.9900
12:9857635:TAA:T	acceptor_gain	0.9900
12:9854379:A:AC	donor_gain	0.9800
12:9854380:C:CC	donor_gain	0.9800
12:9854482:ATT:A	acceptor_gain	0.9800
12:9857468:ACTT:A	donor_loss	0.9800
12:9857469:CTT:C	donor_loss	0.9800
12:9857470:TTA:T	donor_loss	0.9800
12:9857471:TAC:T	donor_loss	0.9800
12:9857472:ACCAT:A	donor_loss	0.9800
12:9857473:C:T	donor_loss	0.9800
12:9854480:AAATT:A	acceptor_gain	0.9700
12:9857472:A:AC	donor_gain	0.9700
12:9857473:C:CC	donor_gain	0.9700
12:9857634:TTAAC:T	acceptor_loss	0.9700
12:9857636:AA:A	acceptor_gain	0.9700
12:9857637:AC:A	acceptor_loss	0.9700
12:9857638:CTGGA:C	acceptor_loss	0.9700
12:9857639:T:A	acceptor_loss	0.9700
12:9857650:C:CT	acceptor_loss	0.9700
12:9857651:A:T	acceptor_loss	0.9700
12:9869538:A:AC	donor_gain	0.9700
12:9869539:C:CC	donor_gain	0.9700
12:9854481:AATT:A	acceptor_gain	0.9600
12:9869539:CTTT:C	donor_gain	0.9600
12:9853408:CCTGC:C	acceptor_loss	0.9500
12:9853409:C:CG	acceptor_loss	0.9500
12:9853410:T:G	acceptor_loss	0.9500

AlphaMissense

994 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:9854446:C:A	W92C	0.995
12:9854446:C:G	W92C	0.995
12:9857543:C:A	W56C	0.995
12:9857543:C:G	W56C	0.995
12:9854407:C:A	W105C	0.991
12:9854407:C:G	W105C	0.991
12:9854479:A:C	F81L	0.989
12:9854479:A:T	F81L	0.989
12:9854481:A:G	F81L	0.989
12:9853319:C:G	C144S	0.985
12:9853320:A:T	C144S	0.985
12:9853330:T:A	R140S	0.985
12:9853330:T:G	R140S	0.985
12:9854448:A:G	W92R	0.985
12:9854448:A:T	W92R	0.985
12:9857534:A:C	S59R	0.984
12:9857534:A:T	S59R	0.984
12:9857536:T:G	S59R	0.984
12:9857523:C:G	C63S	0.983
12:9857524:A:T	C63S	0.983
12:9853373:A:G	L126P	0.982
12:9857594:C:A	W39C	0.981
12:9857594:C:G	W39C	0.981
12:9857545:A:G	W56R	0.980
12:9857545:A:T	W56R	0.980
12:9857585:G:C	F42L	0.980
12:9857585:G:T	F42L	0.980
12:9857587:A:G	F42L	0.980
12:9857522:A:C	C63W	0.979
12:9853326:A:G	W142R	0.978

dbSNP variants (sampled 300 via entrez): RS1000135230 (12:9868848 C>A), RS1000265699 (12:9862790 A>C,G), RS1000271193 (12:9869920 G>A), RS1000299787 (12:9863078 T>C), RS1000525124 (12:9856392 C>T), RS1000569259 (12:9869145 C>G), RS1000734502 (12:9864717 CTAAT>C), RS1000744545 (12:9865146 C>G,T), RS1000799929 (12:9857969 A>G), RS1000895109 (12:9856031 C>T), RS1000962746 (12:9858324 C>T), RS1001450876 (12:9861935 T>A,C), RS1001450984 (12:9869955 T>G), RS1001485350 (12:9863164 A>G), RS1001545748 (12:9868317 T>C)

Disease associations

OMIM: gene MIM:603242 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010725_46	Malaria	1.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Air Pollutants	increases abundance, decreases expression, affects expression	2
Diuron	increases expression, decreases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Particulate Matter	decreases expression, increases abundance	2
GSK-J4	increases expression	1
sotorasib	decreases expression, affects cotreatment	1
urushiol	decreases expression	1
testosterone enanthate	affects expression	1
triphenyl phosphate	affects expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
3,4-dichloroaniline	increases expression	1
arsenite	increases reaction, affects binding	1
sulforaphane	increases expression	1
cobaltous chloride	increases expression	1
zinc chromate	increases abundance, increases expression	1
cupric chloride	increases expression	1
hydroquinone	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases abundance, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
corosolic acid	decreases expression	1
2-palmitoylglycerol	increases expression	1
entinostat	increases expression	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
abrine	increases expression	1
jinfukang	increases expression	1
incobotulinumtoxinA	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1TU	HAP1 CLEC2B (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.